Yong Sang Hong

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Scott Kopetz, Axel Grothey, Rona Yaeger et al. · New England Journal of Medicine · 2019 · 1.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): short-term outcomes of an open-label randomised controlled trial

Sung‐Bum Kang, Ji Won Park, Seung‐Yong Jeong et al. · The Lancet Oncology · 2010 · 1K citations

Medicine, Oncology, Surgery +17

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated <i>BRAF</i> V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero, Axel Grothey, Eric Van Cutsem et al. · Journal of Clinical Oncology · 2021 · 544 citations · Full text

Medicine, Oncology, Pharmacology +16

Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial

Yong Sang Hong, Byung‐Ho Nam, Kyu-pyo Kim et al. · The Lancet Oncology · 2014 · 384 citations

Medicine, Oncology, Surgery +17

Oxaliplatin-Based Adjuvant Chemotherapy for Rectal Cancer After Preoperative Chemoradiotherapy (ADORE): Long-Term Results of a Randomized Controlled Trial

Yong Sang Hong, Sun Young Kim, Ji Sung Lee et al. · Journal of Clinical Oncology · 2019 · 167 citations

Medicine, Oncology, Surgery +17